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a b s t r a c t
Electrospun structures were proposed as scaffolds owing to their morphological and structural simi-
larities with the extracellular matrix found in many native tissues. These ﬁbrous structures were also
proposed as drug release systems by exploiting the direct dependence of the release rate of a drug on the
surface area. An osteogenic differentiation factor, dexamethasone (DEX), was incorporated into elec-
trospun polycaprolactone (PCL) nanoﬁbers at different concentrations (5, 10, 15 and 20 wt.% polymer), in
a single-step process. The DEX incorporated into the polymeric carrier is in amorphous state, as deter-
mined by DSC, and does not inﬂuence the typical nanoﬁbers morphology. In vitro drug release studies
demonstrated that the dexamethasone release was sustained over a period of 15 days. The bioactivity of
the released dexamethasone was assessed by cultivating human bone marrow mesenchymal stem cells
(hBMSCs) on 15 wt.% DEX-loaded PCL NFMs, under dexamethasone-absent osteogenic differentiation
medium formulation. An increased concentration of alkaline phosphatase and deposition of a mineral-
ized matrix was observed. Phenotypic and genotypic expression of osteoblastic-speciﬁc markers
corroborates the osteogenic activity of the loaded growth/differentiation factor. Overall data suggests
that the electrospun biodegradable nanoﬁbers can be used as carriers for the sustained release of
growth/differentiation factors relevant for bone tissue engineering strategies.
! 2010 Elsevier Ltd. All rights reserved.
1. Introduction
Drug release systems are used to improve the therapeutic efﬁ-
cacy and safety of drugs, and enhancing the quality of life of
patients, by delivering them to the site of action at a rate dictated by
the need of the physiological environment [1]. The limitations of
the current drug release systems include suboptimal availability,
limited effective targeting and potential cytotoxicity resulting from
deﬁcient control of the release kinetics. Nanoscale drug release
systems can be designed to tune the release kinetics, to regulate
distribution and to minimize toxic side effects, thereby enhancing
the therapeutic efﬁcacy of a given drug. Drug release with polymer
nanoﬁbers is based on the principle that the dissolution rate of
a drug increases with increased surface area of both the drug and
the corresponding carrier [2]. Unlike common encapsulation
systems involving some complex preparation process [3], electro-
spinning allows the convenient incorporation of therapeutic/
bioactive compounds into the carrier polymer nanoﬁbers in
a single-step process [4]. Indeed, it was observed that enzymes and
antibiotics encapsulated in electrospun nanoﬁbers preserved
higher catalytic activity than the ones incorporated in solvent
casting membranes [5,6].
Electrospinning is considered a promising and versatile pro-
cessing technique, since several polymeric systems [7,8], proteins
[9,10] and even living cells [11] can be applied to develop func-
tionally active nanoﬁbrous structures. Recently, electrospun nano-
ﬁbers were used as a carrier for both hydrophobic and hydrophilic
drugs [6,12e14], where the drug release proﬁle can be controlled by
the modulation of scaffold morphology, porosity, and composition.
In general, the incorporation of bioactive materials (i.e. proteins
and growth factors) within electrospun ﬁbers is achieved by “two-
phase” electrospinning, where an aqueous solution of the biological
molecule is mixed with an organic polymeric solution to form
a biphasic suspension [10,15e17], resulting in the encapsulation of
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aqueous reservoirs within the polymer ﬁbers. In another possible
alternative, two or more components can be co-electrospun
through coaxial capillary channels and integrated into the coree-
shell biphasic ﬁbrous structure [8]. That strategy leads to difﬁculties
in controlling the kinetics of release of those bioactive molecules,
including the burst release effect [18e20]. So far, the research has
been directed to obtain the controlled release of anti-inﬂammatory
agents, antibiotics and anticancer agents [21]. The controlled
release of growth and differentiation factors from electrospun
meshes was not previously explored.
Functional and structural engineering of musculoskeletal tissue,
using a tissue engineering approach, may involve the use of
appropriated cells cultured with speciﬁc growth factors after
seeding in biomaterial scaffolds. Controlled release of therapeutic/
bioactive molecules from biodegradable scaffolds will enhance the
efﬁcacy of tissue engineering approaches [1]. In fact, polymeric
biomaterials are frequently used as release systems, since they can
readily deliver growth factors at the desired site either by direct
protein release approaches or indirectly by gene therapy or by cell
transplantation [22]. Consequently, herein we propose the devel-
opment of electrospun biodegradable nanoﬁbers as a release
system of an established osteogenic differentiation factor e dexa-
methasone e of mesenchymal stem cells (MSCs). Dexamethasone
(DEX) is a synthetic glucocorticoid, which has been shown to
stimulate MSCs proliferation and to support osteogenic lineage
differentiation in vitro, together with b-glycerophosphate and
ascorbic acid, in deﬁned concentrations [23,24]. b-glycer-
ophosphate, the organic phosphate source, plays an important role
in the mineralization process and in modulating osteoblast activi-
ties, such as the alkaline phosphatase (ALP) activity and in the
expression of osteocalcin. Moreover, ascorbic acid is also essential
for increasing cell viability and to stimulate the production of
Collagen type I by osteogenic cells. Therefore, the in vitro osteo-
genesis of MSCs might be more successfully established if the
culturing substrate/scaffold combines at its surface the adequate
physical (i.e. ECM-like nanoﬁbers) and chemical (i.e. growth/
differentiation factors) stimulus. Ultimately, we aim at improving
the efﬁcacy and reduce the total time required to regenerate
a functional bone tissue.
Other authors in the literature reported on electrospun silk
ﬁbroin composite ﬁber scaffolds, containing bone morphogenetic
protein-2 (BMP-2) and/or nanoparticles of hydroxyapatite (nHAP),
and cultured them with human bone marrow-derived mesen-
chymal stem cells (hBMSCs) [25]. The results demonstrated that
those scaffolds, not only support growth and osteogenic differen-
tiation of hBMSCs, but signiﬁcantly enhance calcium deposition
and mRNA transcript levels of bone-related genes. Recently, in
a similar work [26], recombinant human bone morphogenetic
protein-2 (rhBMP-2) was loaded into poly(D,L-lactide-co-glycolide)/
hydroxylapatite (PLGA/HAp) composite electrospun ﬁbrous scaf-
folds. Cell culture experiments with BMSCs showed that the
encapsulation of HAp could enhance cell attachment to scaffolds
and lower cytotoxicity effect. Both works described electrospun
ﬁbrous as release system incorporating a growth/differentiation
factor with known clinical potential (FDA approved) for bone and
cartilage repair [27]. However, the required cocktail of BMPs able to
induce a controlled osteogenic differentiation of mesenchymal
stem cells is still to be deﬁned.
2. Materials and methods
2.1. Production of nanoﬁber meshes loaded with dexamethasone
A polymeric solution of poly(3-caprolactone) (PCL) (TONE", Union Carbide
Chemicals and Plastics Division, New Jersey) 17% (w/v) was prepared using amixture
of chloroform and dimethylformamide (7:3), as described elsewhere [28]. Different
quantities (5, 10, 15 and 20 wt.% polymer) of dexamethasone (SigmaeAldrich,
Germany) were added to the polymeric solution previously prepared, and let to stir
until complete dissolutionwas achieved (approximately during 20min). A tension of
9.5 kV, a current of 3.32 mA, a needle tip-to-ground collector distance of 20 cm and
a ﬂow rate of 1 mL/h were deﬁned as optimized processing conditions for the
speciﬁc material being processed.
2.2. Characterization of dexamethasone-loaded PCL nanoﬁber meshes
DEX-loaded electrospun PCL nanoﬁber meshes were gold sputter-coated (model
SC502, Fisons Instruments, England) for 2 min at 15 mA. Samples were analyzed
using a Scanning Electron Microscope (model S360, Leica Cambridge, England).
Micrographs were recorded at 15 kV with magniﬁcations ranging from 100 to 5000
times.
Fourier Transform Infra-Red Spectroscopy (FTIR) analysis was performed with
the DEX-loaded electrospun PCL nanoﬁber meshes. The samples were powdered,
mixed with KBr, and processed into pellets. FTIR spectra were recorded at 48 scans
with a resolution of 2 cm"1 (Shimadzu e IR Prestige 21)
Differential Scanning Calorimetry (DSC) experiments were carried out using
a DSC Q100 equipment (TA Instrumentse ELNOR). The experiments were conducted
under a nitrogen atmosphere on samples (5e10 mg) packed in aluminium capsules.
The samples were heated in two stages at a constant heating rate of 10 #C/min from
room temperature up to 300 #C. The samples were kept at this temperature for
a period of 2 min and cooled at the same rate to the initial temperature.
2.3. Dexamethasone kinetic release studies
DEX-loaded PCL nanoﬁber meshes (with 4 cm2) wereweighted and incubated at
37 #C in 30 mL of phosphate buffer solution stirred at 60 rpm. Aliquots of 3 mL were
retrieved in predetermined time intervals and the same volume of fresh medium
was added to the suspension. The samples were analyzed by UVeVis spectroscopy at
242 nm (Shimazu UV 1601). The DEX concentration of each sample was calculated
using a standard curve (concentrations ranging from 0.0 to 72 mg/mL), relating the
quantity of DEX with the intensity of light absorbance. The results presented are an
average of three measurements. Calculations of the amount of drug released took
into account the replacement of aliquots with fresh medium. Unloaded control PCL
nanoﬁber meshes (PCL NFMs) were considered as blanks in the performed
quantiﬁcation.
2.4. Expansion, seeding and osteogenic differentiation of human bone marrow
mesenchymal stem cells
Human bone marrow mesenchymal stem cells (hBMSCs) (Biopredic Interna-
tional, France) were isolated and characterized according to the method established
by Delorme and Charbord [29]. hBMSCs were expanded in basal medium consisting
of MEM alpha medium (a-MEM; Gibco, GB) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS; Biochrom AG, Germany) and 1% antibiotic/antimyotic
solution (ﬁnal concentration of penicillin 100 units/mL and streptomycin 100 mg/mL;
Gibco, GB). Cells were cultured at 37 #C in an atmosphere of 5% CO2.
Before the in vitro studies, PCL nanoﬁber meshes loaded with 15 wt.% dexa-
methasone were cut in samples with areas of approximately 1 cm2 and sterilized by
UV irradiation during 1 h on each side of the mesh. Conﬂuent hBMSCs at passage 4
were harvested for seeding onto the DEX-loaded PCL NFMs at a density of
1.0 $ 105 cells/cm2 of the nanoﬁber mesh. Unloaded PCL nanoﬁber meshes were
used as controls. The DEX-loaded PCL NFMs-hBMSCs constructs were cultured
under static conditions, in basal and dexamethasone-absent osteogenic differenti-
ation media (basal medium supplemented with 50 mg/mL ascorbic acid and 10 mM
b-glycerophosphate). The control PCL NFMs-hBMSCs constructs were also cultured
under static condition, in basal and standard osteogenic differentiation media (basal
medium supplemented with 50 mg/mL ascorbic acid, 10 mM b-glycerophosphate and
10"7 M dexamethasone). The constructs were retrieved at different culture times: 7,
14 and 21 days.
2.5. Cell morphology and distribution, and chemistry of deposited matrix
For scanning electron microscopy (SEM) observation, the samples were ﬁxed
with 2.5% Glutaraldehyde (Sigma; USA) in a Phosphate Buffer Saline solution
(Sigma; USA) during 1 h at 4 #C. The samples were further dehydrated through
increasing series of ethanol concentrations and let to dry overnight. Previous to the
analysis by SEM (model S360, Leica Cambridge, England) equipped with an energy
dispersive spectrometer (EDS; link-eXL-II), the samples were gold or carbon sputter-
coated (sputter coater model SC502, Fisons Instruments, England).
2.6. Cell viability and proliferation assessment
Cell viability for each culturing time was determined using the CellTiter 96#
AQueous One Solution Cell Proliferation Assay (Promega, USA). This assay is based on
the bioreduction of a tetrazolium compound, 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfofenyl)-2H-tetrazolium [MTS], into a water-soluble
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brown formazan product. The absorbance was measured at 490 nm in a microplate
reader (SynergieHT,Bio-Tek,USA), beingrelatedwith thequantityof formazanproduct
and directly proportional to the number of living cells in the constructs. Three samples
of each nanoﬁber mesh per time point were characterized.
Cell proliferation was quantiﬁed by the total amount of double-stranded DNA,
along the culturing time. Quantiﬁcation was performed using the Quant-iT" Pico-
Green dsDNA Assay Kit (Invitrogen", Molecular Probes", Oregon, USA), according
to the instructions of the manufacturer. Brieﬂy, cells in the construct were lysed by
osmotic and thermal shock and the supernatant used for the DNA quantiﬁcation
assay. The ﬂuorescence of the dye was measured at an excitationwavelength of 485/
20 nm and at an emission wavelength of 528/20 nm, in a microplate reader (Syn-
ergie HT, Bio-Tek, USA). Triplicates were made for each sample and per culturing
time. The DNA concentration for each sample was calculated using a standard curve
(DNA concentration ranging from 0.0 to 1.5 mg/mL) relating quantity of DNA and
ﬂuorescence intensity.
2.7. Alkaline phosphatase quantiﬁcation
The concentration of alkaline phosphatase (ALP) was determined for all time
culture periods, using the lysates used for DNA quantiﬁcation. Brieﬂy, the ALP
quantity was assessed using the p-nitrophenol assay, in which the colourless
nitrophenyl phosphate disodium salt (pnPP; Sigma, USA) is hydrolysed by the ALP
(Sigma, USA) at pH 10.5 and temperature of 37 #C to form yellow free p-nitrophenol.
The reaction was stopped by addition of 2 M NaOH (Panreac Quimica, Spain) and the
absorbance read at 405 nm in a microplate reader (Bio-Tek, Synergie HT, USA).
Standards were prepared with 10 mmol/mL p-nitrophenol (pNP; Sigma, USA) solu-
tion, to obtain a standard curve ranging from 0 to 0.250 mmol/mL. Triplicates of each
sample and standard were made, and the ALP concentrations read off from the
standard curve.
2.8. Alizarin red staining
After culture, the DEX-loaded nanoﬁber meshes-hBMSCs constructs were ﬁxed
in 10% formalin solution neutral buffer (SigmaeAldrich, Germany) for 30 min and
maintained in phosphate buffer saline (PBS) until further use. The constructs were
further stained with a 2% Alizarin Red solution (Merk, Germany) in distilled water
for 5 min, and ﬁnally washed with distilled water. Stained constructs were observed
under an optical microscope (BX61, Olympus Corporation, Germany) and images
captured by a digital camera (DP70, Olympus Corporation, Germany).
2.9. Immunodetection of bone-speciﬁc proteins
Immunocytochemistry was performed following the streptavi-
dinebiotineperoxidase complex approach (R.T.U. Vectastain# Universal Elite# ABC
kit; Vector Laboratories Inc., Burlingame, CA), using a rabbit polyclonal antibody
against osteopontin (Abcam Ltd., Cambridge, UK; dilution 1:1500), a mouse
monoclonal antibody against osteocalcin (clone OC4-30, Abcam Ltd., Cambridge,
UK; dilution 1:100) and a rabbit polyclonal antibody against bone sialoprotein II
(Chemicon# International Inc., Germany; dilution 1:2500). Prior to the immunocy-
tochemistry procedure, constructs were ﬁxed in 10% formalin solution neutral buffer
(SigmaeAldrich, Germany) for 30 min and maintained in phosphate buffer saline
(PBS) until further use. The constructs were treated with 0.3% hydrogen peroxide in
methanol during 30 min to inactivate the endogenous peroxidases. After washing
with PBS, the constructs were blocked with 2.5% normal horse serum for 20 min at
room temperature to avoid unspeciﬁc reactions. Primary antibodies were incubated
overnight at 4 #C. Negative controls were set in the absence of primary antibodies
incubation. After washing in PBS, the samples were incubated for 30 min with
biotinylated secondary antibody anti-rabbit/mouse IgG, followed by incubationwith
streptavidineperoxidase complex (Elite ABC Reagent). The immune reaction was
visualized using DAB as a chromogen (DAB Substrate Reagent from Peroxidase
Substract Kit; Vector Laboratories Inc, Burlingame, CA). The constructs were
observed under an optical microscope (BX61, Olympus Corporation, Germany) and
images captured by a digital camera (DP70, Olympus Corporation, Germany).
2.10. RNA isolation and real-time quantitative polymerase chain reaction (qPCR)
Total RNA from the constructs was extracted using the Trizol# (Invitrogen, Life
Technologies Inc., UK) method according to the manufacturer’s directions. Brieﬂy, at
each culturing time the constructs were washed with PBS, immersed in Trizol and
storage at "80 #C until further use. Proteins were removed with chloroform
extraction, and the RNA pellets were washed once with isopropyl alcohol and once
with 70% ethanol. The total RNA pellets were reconstituted in Rnase free water
(Gibco, Invitrogen, UK).
Reverse transcriptase (RT)-PCR was performed according to the protocol from
iScript" cDNA synthesis kit (BioRad, Hercules, CA, USA). Brieﬂy, a reaction mixture
consisting of 1$ iScript Reaction Mix, 1 mL iScript Reverse Transcriptase, RNA
template (300 ng total RNA) and nuclease-free water was prepared, in 20 mL of total
volume. The single-strand cDNA synthesis occurred by incubating the complete
reaction mixture 5 min at 25 #C, followed by 30 min at 42 #C and terminated by an
incubation at 85 #C for 5 min.
Ampliﬁcation of the target cDNA for real-time PCR quantiﬁcationwas performed
according to manufacturer, using 2 mL RT cDNA products, 1 mM each primer (bone-
speciﬁc primer sets listed in Table 1), 1$ iQ SYBR Green Supermix (BioRad, Hercules,
CA, USA) and nuclease-free water, in a ﬁnal volume of 25 mL. Forty-four cycles of
denaturation (95 #C, 10 s), annealing (temperature dependent on the gene, 30 s) and
extension (72 #C, 30 s) were carried out in the gradient thermocycler MiniOpticon
real-time PCR detection system (BioRad, Hercules, CA, USA) for all genes. The
transcripts expression data were normalized to the housekeeping gene glyceralde-
hydes-3-phosphate-dehygrogenase (GAPDH) and the relative quantiﬁcation calcu-
lated by the ∆CT method.
2.11. Statistical analysis
Statistical analysis was performed using the SPSS statistic software (Release
15.0.0 for Windows). Firstly, a ShapiroeWilk test was used to ascertain about the
data normality. The results indicated that nonparametric tests should be used for
all comparisons. A KruskaleWallis test followed by Turkey’s HSD test were per-
formed to analyze the effect of the DEX-loaded electrospun nanoﬁbrous meshes on
the hBMSCs’ viability and proliferation, ALP quantiﬁcation, and osteogenic geno-
type. P values lower than 0.01 were considered statistically signiﬁcant.
3. Results
3.1. Physicochemical properties of the dexamethasone-loaded
electrospun PCL nanoﬁber meshes
In the present work, a glucocorticoid drug e dexamethasone e
was dissolved at different concentrations (5, 10, 15 and 20 wt.%
polymer) in the polymeric solution to be electrospun. A mesh-like
structure composed by randomly distributed ﬁbers with diameters
ranging from 150 nme1.6 mm (Fig. 1BeE) was produced. The
incorporation of dexamethasone at concentrations ranging from 5
to 15 wt.% (Fig. 1BeD) shows the appearance of thinner ﬁbers in
larger number than in the control nanoﬁber meshes (Fig. 1A).
However, those differences in morphology are probably insufﬁcient
to induce any speciﬁc cell response. This observation was expected
since the solvent is able to dissolve simultaneous the polymer and
the incorporated drug. In this way, the drug is very well dispersed
in the bulk polymeric matrix of the electrospun nanoﬁbers without
inducing signiﬁcant morphological variation of the electrospun
ﬁbers. Relevant morphological alteration, namely an increment of
nanoﬁbers diameter, was observed only in the electrospun meshes
with an incorporation of 20 wt.% DEX (Fig. 1E).
To conﬁrm the presence of dexamethasone incorporated in the
electrospun PCL nanoﬁbers an FTIR analysis was performed. Fig. 2
shows the spectra of PCL nanoﬁbers, raw dexamethasone and
also of the different DEX-loaded electrospun PCL nanoﬁber meshes.
The characteristic peaks of dexamethasone at 900 and 1650 cm"1
are observed in the nanoﬁber meshes prepared with the different
Table 1
Primers list of osteogenic markers.
Gene Primer sequences (50-30) Tm (#C)
ALP Sense CTCCTCGGAAGACACTCTG 60.0
Antisense AGACTGCGCCTGGTAGTTG
OP Sense GGGGACAACTGGAGTGAAAA 58.4
Antisense CCCACAGACCCTTCCAAGTA
BSP Sense CAACAGCACAGAGGCAGAAAAC 59.9
Antisense CCTCGTATTCAACGGTGGTG
OC Sense CTGAGAGGAGCAGAACTGG 61.4
Antisense GGCAGCGAGGTAGTGAAGAG
Runx2 Sense TTCCAGACCAGCAGCACTC 58.1
Antisense CAGCGTCAACACCATCATTC
Osterix Sense CCCTTTACAAGCACTAATGG 57.1
Antisense ACACTGGGCAGACAGTCAG
GAPDH Sense ACAGTCAGCCGCATCTTCTT 58.4
Antisense GACAAGCTTCCCGTTCTCAG
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DEX concentrations, which conﬁrms the presence of the gluco-
corticoid in the polymeric matrix.
Thermal analysis of the DEX-loaded nanoﬁber meshes was
carried out to ascertain about the crystalline state of the incor-
porated dexamethasone. Fig. 3A shows the DSC thermograms of
PCL nanoﬁber meshes and raw dexamethasone. In this graph is
possible to observe the melting peaks of the polymer at 56.9 #C
and of dexamethasone at 262.2 #C. However, the characteristic
endothermic peak of dexamethasone is not present in the DEX-
loaded nanoﬁber meshes (Fig. 3B). These thermal properties of
Fig. 1. Morphological characterization of a typical electrospun PCL nanoﬁber mesh (A) and the electrospun nanoﬁber meshes incorporating different concentrations of dexa-
methasone: 5 wt.% (B), 10 wt.% (C), 15 wt.% (D) and 20 wt.% (E).
Fig. 2. FTIR spectra of raw dexamethasone, control PCL NFMs, DEX-loaded PCL NFMs at 10 wt.%, 15 wt.% and 20 wt.%.
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DEX-loaded PCL nanoﬁber meshes suggest that dexamethasone,
precipitated from the polymeric/organic solution during the
electrospinning processing, is not in its crystalline state when
incorporated in the nanoﬁber meshes. This is a typical observa-
tion, since the mobility of the DEX inside the ﬁbers is highly
hindered.
3.2. Release kinetics of dexamethasone from the electrospun PCL
nanoﬁber meshes
The release proﬁle of dexamethasone from the different DEX-
loaded PCL NFMs was followed during 21 days, in accordance with
the culture time usually needed to observe a complete osteogenic
Fig. 3. DSC thermogram of control PCL NFMs (black line) and raw dexamethasone (grey line) (A), and DEX-loaded PCL nanoﬁbers at 5 wt.%, 10 wt.%, 15 wt.% and 20 wt.% (B).
Fig. 4. Release proﬁle of the different dexamethasone concentrations incorporated into the electrospun PCL nanoﬁber meshes.
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differentiation of MSCs in vitro. As depicted in Fig. 4, a signiﬁcant
initial release of dexamethasone e burst release ewas observed in
the case of PCL NFMs incorporating above 5 wt.% of the growth/
differentiation factor. It was noticed that a higher amount of drug
lead to a faster release rate. After 100 h, a slow sustained release of
dexamethasone was observed for all systems. Considering the
release proﬁles of the different DEX-loaded PCL NFMs and the
dexamethasone concentrations achieved, the 15 wt.% DEX-loaded
PCL NFMs was chosen for further in vitro biological assays.
3.3. Biological activity of the dexamethasone released from the
electrospun nanoﬁber meshes
To ascertain about the biological activity, and inherent structural
integrity, of the released dexamethasone from the electrospun PCL
NFMs, human bone marrow mesenchymal stem cells (hBMSCs)
were cultured on15wt.%DEX-loadedPCLNFMs. FromtheMTSassay
data (Fig. 5) it was possible to observe that, until the 14th day of
culture, the different culture conditions did not induce signiﬁcant
changes over hBMSCs viability (p > 0.01). However, at day 21,
hBMSCs cultured on DEX-loaded NFMs on dexamethasone-absente
osteogenic differentiation medium (NFMþDEX_Osteo), on DEX-
loaded NFMs (NFMþDEX_Basal) and on control PCL NFMs
(NFM_Basal) on basal medium showed signiﬁcant lower viability
than those cultured on standard osteogenic differentiation medium
(NFM_Osteo) (p < 0.01). Moreover, for this culturing time, DEX-
loaded NFMs cultured on basal (NFMþDEX_Basal) and dexametha-
sone-absent osteogenic differentiation media (NFMþDEX_Osteo)
presented signiﬁcantly higher hBMSCs’ viability than those cultured
on control PCL NFMs under basal conditions (NFM_Basal) (p< 0.01).
Complementary to the analysis of hBMSCs’ viability along the course
of the experiment, the proliferation or replication rate of those cells
was also quantiﬁed based on the DNA content (Fig. 6). DEX-loaded
NFMs constructs cultured on dexamethasone-absent osteogenic
differentiationmedium (NFMþDEX_Osteo) present signiﬁcant lower
proliferation capability than hBMSCs cultured under all the other
conditions (p < 0.01). Conversely, control PCL NFMs cultured under
basal medium (NFM_Basal) demonstrated signiﬁcantly higher DNA
concentration than all the other substrates and corresponding
culture medium (p < 0.01), just for the 14th day.
Despite theabovedescribedproliferative cell population cultured
on the DEX-loaded PCL NFMs under basal (NFMþDEX_Basal)
or dexamethasone-absent osteogenic differentiation media
Fig. 5. Box plot of the hBMSCs viability (MTS assay) cultured on NFM_Osteo,
NFM_Basal, NFMþDEX_Osteo and NFMþDEX_Basal, after 7, 14 and 21 days. Data were
analyzed by nonparametric way of a KruskaleWallis test followed by Tukey’s HSD test:
a, denotes signiﬁcant differences compared to NFM_Osteo; b, denotes signiﬁcant
differences compared to NFM_Basal.
Fig. 6. Box plot of the hBMSCs proliferation (DNA concentration) cultured on
NFM_Osteo, NFM_Basal, NFMþDEX_Osteo and NFMþDEX_Basal, after 7, 14 and 21 days.
Data were analyzed by nonparametric way of a KruskaleWallis test followed by
Tukey’s HSD test: a denotes signiﬁcant differences compared to NFM_Osteo; b denotes
signiﬁcant differences compared to NFM_Basal; c denotes signiﬁcant differences
compared to NFMþDEX_Osteo.
Fig. 7. Box plot of the alkaline phosphatase (ALP) concentration produced by hBMSCs
cultured on NFM_Osteo, NFM_Basal, NFMþDEX_Osteo and NFMþDEX_Basal, after 7, 14
and 21 days. Data were analyzed by nonparametric way of a KruskaleWallis test fol-
lowed by Tukey’s HSD test: a, denotes signiﬁcant differences compared to NFM_Osteo;
b, denotes signiﬁcant differences compared to NFM_Basal; c, denotes signiﬁcant
differences compared to NFMþDEX_Osteo.
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(NFMþDEX_Osteo), the expression of alkaline phosphatase (ALP) is
similar to theoneobserved in control PCLNFMsculturedon standard
osteogenic differentiation medium (NFM_Osteo) (p > 0.01) (Fig. 7).
An exception was observed for the 14 days of culture: hBMSCs
cultured on DEX-loaded NFMs under dexamethasone-absent
conditions (NFMþDEX_Osteo) produced signiﬁcant higherquantities
of ALP than the control PCL NFMs under osteogenic conditions
(NFM_Osteo) (p < 0.01). Undifferentiated hBMSCs cultured on the
control PCL NFMs (NFM_Basal) produce negligible quantities of ALP,
asdepictedby thesigniﬁcantly lowerALPconcentration compared to
all the other substrates and corresponding culture medium
(p < 0.01). Consequently, further characterization of the osteogenic
phenotype and genotype herein reported does not include this
condition.
The morphology and distribution of the hBMSCs cultured on
DEX-loaded NFM was analyzed by SEM. The cells interacted with
the ﬁbrous structure, bridging contiguous ﬁbers and formed
a dense cellular construct that was clearly visible at day 7 (Fig. 8A).
It was also possible to observe deposition of minerals over the
dense cellular layer from day 14 onward (Fig. 8B and C), resulting
from thematrixmineralization that occurs along the differentiation
of hBMSCs into osteoblasts. To conﬁrm the matrix mineralization,
an alizarin red staining was performed to speciﬁcally detect the
calcium present in those mineralized nodules. The intense red/
purple dots dispersed in the construct correspond to the mineral-
ized nodules, after 14 and 21 days of hBMSCs culture on DEX-
loaded NFM under dexamethasone-absent osteogenic differentia-
tion medium formulation (Fig. 8D and E). Using Energy Dispersive
Spectrometry (EDS) it was possible to identify the elemental
composition of the minerals deposited on the DEX-loaded PCL
NFM-hBMSCs constructs (Fig. 8F). EDS data conﬁrms the presence
of Calcium and Phosphorous deposition by the adjacent cells, and
the increasing amount from day 14e21 of hBMSCs culture under
dexamethasone-absent osteogenic differentiation medium formu-
lation. Those observations were not found in control PCL NFM
cultured with hBMSCs under standard osteogenic differentiation
conditions, nor in the DEX-loaded PCL NFM culturewith hBMSCs on
basal medium (data not included here).
The osteogenic phenotype of hBMSCs seeded onto DEX-loaded
nanoﬁber meshes was also assessed by the immunodetection of
some speciﬁc osteoblastic proteins, namely osteopontin, bone sia-
loprotein and osteocalcin. Photomicrographs indicate a progressive
expression of the speciﬁc osteoblastic glycoprotein osteopontin on
the DEX-loaded NFMs-hBMSCs constructs during the 21 days of
culture (Fig. 9). In the cases of bone siaoloprotein and osteocalcin
protein, the maximum expression seems to be achieved at the 14th
day of hBMSCs culture under dexamethasone-absent osteogenic
differentiation medium. Similar osteoblastic protein expression
patternwas observed in the control PCL NFM culturedwith hBMSCs
under standard osteogenic differentiation conditions and, also, in
the DEX-loaded PCL NFM culture with hBMSCs in basal medium
(data not shown).
Complementary to the phenotypic analysis, a genotypic quan-
tiﬁcation of the expression of some bone-speciﬁc genes was per-
formed to ascertain about the differentiation level of the seeded
hBMSCs on DEX-loaded PCL NFMs. The relative expression of those
Fig. 8. SEM micrographs of hBMSCs cultured on DEX-loaded NFMs during 7 (A), 14 (B) and 21 days (C). Higher magniﬁcations are shown to evidence the mineralization nodules
produced by the hBMSCs. Alizarin red staining of the DEX-loaded NFMs-hBMSCs constructs after 14 (D) and 21 days (E). Energy dispersive spectrometer (EDS) spectra of the calcium
phosphates nodules produced by hBMSCs cultured on DEX-loaded NFMs after 14 and 21 days (F).
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genes was normalized against the housekeeping gene GAPDH and
compared to hBMSCs cultured on control PCL NFM under standard
osteogenic differentiation conditions. A constitutive expression of
all mRNA transcripts (i.e. Alkaline Phosphatase, Osteopontin, Bone
Sialoprotein, Osteocalcin, Runx-2 and Osterix) was observed during
the 21 days of culture. Although Alkaline Phosphatasewas present in
a stable fashion, its expression is signiﬁcantly lower in hBMSCs
cultured on DEX-loaded PCL NFMs, in both culture conditions
(p < 0.01) (Fig. 10). Among those bone-speciﬁc genes, Bone Sialo-
protein and Osterix were the highest expressed, followed by the
Osteopontin gene.
4. Discussion
4.1. Electrospun nanoﬁber meshes incorporating and releasing
dexamethasone
The rate of drug release depends on a multitude of factors, such
as the nature of the polymer matrix (i.e. chemical composition,
backbone stability and water solubility), matrix architecture,
loading capacity and drugematrix interaction. Therefore, for the
development of an ideal drug release system, the polymer should
be biodegradable, have appropriate degradation rate, nontoxic
degradation products, appropriate solubility and simplicity of
fabrication [30]. The herein developed drug carrier was based on
the convenient processing of nanoﬁbrous structures by
electrospinning, using an adequate organic solvent to simulta-
neously dissolve the biodegradable polymer e polycaprolactone e
and the incorporated drug e dexamethasone. This drug release
system allows a suitable interaction between PCL and dexameth-
asone, being the drug well distributed in the polymer matrix.
Consequently, the drug presents a good physicochemical interac-
tionwith the polymer. The structural integrity of the differentiation
factor, as well as its biological activity could be maintained during
the processing step. The large surface area associated with the
nanoﬁber mesh allows fast and efﬁcient solvent evaporation, which
limits the period of time of the incorporated drug to recrystallize,
favouring the maintenance of amorphous dispersed phase [2,6,13].
The presence of amorphous dexamethasone in our polymeric
carrier was also observed in our DSC data.
The most widely investigated release system for the encapsu-
lation of bioactive compounds is micro- and nanoparticles. Nano-
particles have facility to diffuse through cell membranes, allowing
controlling or modifying the cell activity. The osteogenic differen-
tiation factor herein incorporated in electrospun biodegradable
nanoﬁbers was already studied by our group and others in different
drug release systems, including micro- and nanoparticles and
scaffolds [31e39]. Those polymeric drug release systems are based
in starchepolycaprolactone (SPCL) microparticles or carbox-
ymethylchitosan/poly(amidoamine) dendrimer (CMCht/PAMAM)
nanoparticles. Both devices were intended to be used as part of an
injectable system or in a polymeric 3D scaffold. In the present work
Fig. 9. Immunodetection of some bone-speciﬁc proteins, namely Osteopontin, Bone Sialoprotein and Osteocalcin, expressed by hBMSCs cultured on DEX-loaded NFMs during 7, 14
and 21 days.
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it was presented a dexamethasone release system, based on elec-
trospun biodegradable nanoﬁbers as carrier. It is aimed at devel-
oping a system that simultaneously acts as a scaffold for
mesenchymal stem cells differentiation toward the osteogenic
lineage. The next generation of engineered tissues relies on the
development of biodegradable scaffolds as physical supports to
release bioactive molecules that control cell attachment, prolifer-
ation and differentiation [40].
Due to the relatively slowwetting, as a consequence of the highly
hydrophobic character of the PCLNFMand its slowdegradation rate,
it was possible to deduce that dexamethasone release occurred
primarily by diffusion, demonstrating that a biodegradable nano-
ﬁbrous system can be used to obtain a release proﬁle that was
effective in differentiating stem cells. The burst release effect
common inpolymer-based release systems, is connected to the high
gradients of concentration observedat the initial stages of release. In
the systemof 20wt.% DEX-loaded PCLNFMs, the burst release effect
maybe primarily caused byan imperfect distribution/entrapmentof
the dexamethasone into the polymer matrix or by their tendency to
migrate to the nanoﬁber surface during the electrospinning process
[41]. As the nanoﬁbers are placed in an aqueous environment, at the
initial stagewater penetrates into the nanoﬁbers surface and a large
amountof dexamethasone is faster releaseddue to the initial surface
erosion. Subsequently, water permeates into the bulk of the nano-
ﬁbers causing polymer swelling, bond cleavage and bulk erosion,
generating interconnecting pores and channels within nanoﬁbers
that allow the slow sustained release of the remaining dexametha-
sone [41].
4.2. Bioactivity of the dexamethasone loaded in the electrospun
nanoﬁber meshes
Drug release systems are developed to maximize the thera-
peutic activity while minimizing the toxic side effects of drugs.
However, the scope of those devices is limited for targeting tissues
rather than individual cells [1]. In tissue engineering, the required
bioactive molecules are typically supplied to the cells growing on
the scaffold in the culture medium, in the soluble form. The present
drug carrier was designed to operate as a synthetic extracellular
matrix e scaffold e for mesenchymal stem cell growth and,
simultaneously, to allow a direct supply of the differentiation factor
to the adherent cells. It is intended to supply locally the required
amount needed to promote the proliferation and differentiation
towards the osteogenic lineage. To validate this hypothesis, an
osteogenic differentiation study was conducted. The osteogenic
differentiation is sensitive to the dose and duration of exposure to
the glucocorticoid [42]. Jaiswal et al. suggested that the effective
concentration of DEX for the osteogenic differentiation of MSCs
should be in the range of 10e100 nM, showing toxic effects at
1000 nM [24].
The electrospun PCL NFMs loaded with 15 wt.% dexamethasone
were cultured with hBMSCs under dexamethasone-absent
Fig. 10. Relative expression of bone-speciﬁc transcripts, namely Alkaline Phosphatase, Osteopontin, Bone Sialoprotein, Osteocalcin, Runx2 and Osterix, by hBMSCs cultured on
NFM_Osteo, NFMþDEX_Osteo and NFMþDEX_Basal, during 7, 14 and 21 days. The expression of these genes was normalized against the housekeeping gene GAPDH and calculated by
the DCT method. Data were analyzed by nonparametric way of a KruskaleWallis test followed by Tukey’s HSD test: a, denotes signiﬁcant differences compared to NFM_Osteo.
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osteogenic differentiation medium formulation. Our biological
results conﬁrm the biological activity of the incorporated dexa-
methasone, as shown by the increased amount of deposited
calcium phosphates produced by the differentiated cells (also
stained by alizarin red and identiﬁed by EDS). Additionally, the
increasing concentration of the enzyme alkaline phosphatase (ALP)
also conﬁrms the osteoblastic differentiation and mineralization of
hBMSCs cultured on DEX-loaded PCL NFMs. In fact, this enzyme
catalyses the splicing of phosphate from nonphosphoric esters,
constituting a biochemical indicator of the presence of osteoblasts
and the deposition of mineralized ECM, since MSCs produce
negligible amounts of this enzyme, as depicted by our results. This
hypothesis of osteoblastic differentiation was conﬁrmed by the
expression of speciﬁc osteoblastic glycoproteins, namely osteo-
pontin and bone sialoprotein, which are also present in the ECM of
bone. The deposition and mineralization of ECM, previously
observed in the SEM micrographs, stained with alizarin red and
chemically identiﬁed by EDS, were also conﬁrmed by the immu-
nodetection of the osteocalcin protein, which binds strongly to
apatite and calcium.
In the literature three periods were identiﬁed on the osteogenic
differentiation of embryonic stem cells (ES) [43], corresponding to
the expression pattern of the osteoblastic markers: a proliferative
phase, which is followed by the period of matrix deposition, and
lastly the mineralization phase. The highest expression peak of
Osteopontin mRNA at 14 days of hBMSCs culture determines the
end of the matrix deposition phase and the beginning of the
mineralization phase. The very high expression level of Bone Sia-
loprotein conﬁrms the presence of mature osteoblasts, corre-
sponding to the mineralization phase. Finally, this phase was
conﬁrmed by the expression of Osteocalcin mRNA, which is
designed as the essential marker of the mineralization phase,
reaching a maximum expression just before or during tissue
mineralization [30]. Therefore, considering our results and the
differences in the cell type used, themost important genes involved
in the osteogenic differentiation process were constitutively
expressed, conﬁrming the matrix deposition and mineralization by
hBMSCs cultured and differentiated on DEX-loaded NFMs. The
main speciﬁc transcription factors involved in the osteogenesis
were also quantiﬁed by qPCR, namely the core binding factor a 1/
runt-related gene (Cbfa1/Runx-2) and Osterix (Osx). Cbfa1/Runx2was
already shown to be involved in the two steps of the differentiation
process: driving stem cells into preosteoblasts and also preosteo-
blasts into osteoblasts. Osterix acts only during the last stage
involving the transition preosteoblast/osteoblast [44,45]. Our data
shows that Osterix and Bone Sialoprotein genes were the bone-
speciﬁc transcripts with the highest expression levels. Those results
further corroborate the successful differentiation of hBMSCs into
osteoblasts on DEX-loaded NFMs. Similar osteoblastic gene
expression patterns were observed for hBMSCs culture on DEX-
loaded NFMs under basal conditions. This surprising result
corroborates the hypothesis that even a transient exposure of stem
cells to DEX (speciﬁcally during the 1st week) may be effective in
inducing and maintaining the osteoblastic phenotype [24].
5. Conclusions
We report herein the development of electrospun biodegrad-
able nanoﬁbers as a release system of an established osteogenic
differentiation agent of hBMSCs e dexamethasone. Dexametha-
sone was incorporated at different concentrations (5, 10, 15 and
20 wt.% polymer) in the polymeric nanoﬁbers, being the 15 wt.%
release system selected for cell studies because of its sustained
release. An increased alkaline phosphatase concentration and
deposition of mineralized matrix were observed on
dexamethasone releasing nanoﬁbrous system cultured with
hBMSCs in dexamethasone-absent osteogenic differentiation
medium. The phenotypic and genotypic expression of osteoblastic-
speciﬁc markers conﬁrmed the osteogenic inducing potential of the
loaded growth/differentiation factor. Thus, an osteogenic inductive
scaffold was developed aimed for bone tissue engineering
strategies.
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